These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 35213980)

  • 1. The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.
    Ramos TI; Villacis-Aguirre CA; López-Aguilar KV; Santiago Padilla L; Altamirano C; Toledo JR; Santiago Vispo N
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
    Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
    Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
    Agrahari V; Agrahari V
    Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.
    Dobrovolskaia MA
    J Control Release; 2015 Dec; 220(Pt B):571-83. PubMed ID: 26348388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.
    Dobrovolskaia MA; McNeil SE
    J Control Release; 2013 Dec; 172(2):456-66. PubMed ID: 23742883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in development of nanoparticle-based therapeutics.
    Desai N
    AAPS J; 2012 Jun; 14(2):282-95. PubMed ID: 22407288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Methods and Approaches for Safety Evaluation of Nanoparticle Formulations: A Focus Towards
    Tirumala MG; Anchi P; Raja S; Rachamalla M; Godugu C
    Front Pharmacol; 2021; 12():612659. PubMed ID: 34566630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
    Eifler AC; Thaxton CS
    Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale.
    Feng J; Markwalter CE; Tian C; Armstrong M; Prud'homme RK
    J Transl Med; 2019 Jun; 17(1):200. PubMed ID: 31200738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
    Bhattacharjee S; Brayden DJ
    Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.